✦ LIBER ✦

7122 Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (mRCC): preliminary results

✍ Scribed by Barrios, C.H.; Hernandez-Barajas, D.; Brown, M.P.; Lee, S.H.; Fein, L.; Liu, J.H.; Hariharan, S.; Martell, B.; Yuan, J.; Rha, S.Y.

Book ID: 122885417
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 71 KB
Volume: 7
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(09)71455-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of continuous once-daily

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

✍ Carlos H. Barrios; David Hernandez-Barajas; Michael P. Brown; Se-Hoon Lee; Luis 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 855 KB

4504 ORAL A phase II study of continuous

4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results

✍ Escudier, B.; Srinivas, S.; Roigas, J.; Gillessen, S.; Harmenberg, U.; De Mulder 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 78 KB

SUNITINIB AS FIRST-LINE TREATMENT FOR ME

SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC): UPDATED RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS FROM A PHASE III RANDOMISED TRIAL

✍ S. Oudard; R.J. Motzer; M.D. Michaelson; T.E. Hutson; P. Tomczak; R.M. Bukowski; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Phase II Randomized Trial Comparing Sequ

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

✍ Motzer, R. J.; Barrios, C. H.; Kim, T. M.; Falcon, S.; Cosgriff, T.; Harker, W. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 282 KB

3002 Final quality of life (QOL) results

3002 Final quality of life (QOL) results with geographical analysis for sunitinib versus interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

✍ D. Cella; M.D. Michaelson; A.G. Bushmakin; J.C. Cappelleri; C. Charbonneau; S.T. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Phase III Study of Sunitinib Malate (SU1

Phase III Study of Sunitinib Malate (SU11248) Versus Interferon-α as First-Line Treatment in Patients with Metastatic Renal Cell Carcinoma

✍ Kesava Reddy; Ronald M. Bukowski 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB